Current concepts for PrEP adherence in the PrEP revolution: from clinical trials to routine practice

被引:146
|
作者
Haberer, Jessica E. [1 ,2 ]
机构
[1] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA
[2] Harvard Univ, Sch Med, Dept Med, Boston, MA USA
基金
美国国家卫生研究院;
关键词
adherence; preexposure prophylaxis; HIV PREEXPOSURE PROPHYLAXIS; ANTIRETROVIRAL THERAPY; SELF-REPORT; RISK; MEN; SEX; PREVENTION; INFECTION; TENOFOVIR; INTERVENTIONS;
D O I
10.1097/COH.0000000000000220
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Purpose of reviewThe review describes the current understanding of adherence to oral preexposure prophylaxis (PrEP), methods for adherence measurement, approaches to supporting PrEP adherence, and guidance for defining PrEP adherence goals within the larger context of HIV prevention.Recent findingsPrEP adherence has generally been higher in recent trials, open-label extensions, and demonstration projects compared with the initial clinical trials; potential explanations include known PrEP efficacy and different motivations to take PrEP. Recent studies have explored adherence monitoring through electronic pill containers, short message service (SMS), and drug concentrations in hair and dried blood spots. The few PrEP adherence interventions developed to date include combinations of enhanced counseling, feedback of objective adherence measurement, and SMS. Conceptualization of PrEP adherence is evolving. The goal is not 100% adherence indefinitely, as it was in clinical trials. PrEP adherence should be defined with respect to HIV exposure, which varies over time by sexual behavior and use of other prevention strategies.SummaryPrEP adherence beyond clinical trials has generally been high enough to achieve reliable HIV prevention. Future efforts to measure and support PrEP adherence should focus on the context of risk for HIV acquisition, accounting for dynamic behaviors and choices among HIV prevention options.
引用
收藏
页码:10 / 17
页数:8
相关论文
共 50 条
  • [31] Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery
    Susanne Doblecki-Lewis
    Stephanie Cohen
    Albert Liu
    Current Treatment Options in Infectious Diseases, 2015, 7 (2) : 101 - 112
  • [32] Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials
    Kawango Agot
    Douglas Taylor
    Amy L. Corneli
    Meng Wang
    Julie Ambia
    Angela D. M. Kashuba
    Caleb Parker
    Ansley Lemons
    Mookho Malahleha
    Johan Lombaard
    Lut Van Damme
    AIDS and Behavior, 2015, 19 : 743 - 751
  • [33] The Effect of Disclosure of PrEP Use on Adherence Among African Young Women in an Open-Label PrEP Study: Findings from HPTN 082
    Geetha Beauchamp
    Sybil Hosek
    Deborah Donnell
    Kwun C. G. Chan
    Peter L. Anderson
    Bonnie J. Dye
    Nyaradzo Mgodi
    Linda-Gail Bekker
    Sinead Delany-Moretlwe
    Connie Celum
    AIDS and Behavior, 2024, 28 : 1512 - 1521
  • [34] HIV Pre-Exposure Prophylaxis (PrEP) in a Brazilian Clinical Setting: Adherence, Adverse Events, Sexual Behavior, and Sexually Transmitted Infections
    Pinto Barbosa, Ana Karina
    Monteiro, Polyana
    Montenegro, Demetrius
    Lyra Batista, Joanna D'Arc
    Montarroyos, Ulisses Ramos
    ARCHIVES OF SEXUAL BEHAVIOR, 2022, 51 (05) : 2603 - 2611
  • [35] Reaching at-risk women for PrEP delivery: What can we learn from clinical trials in sub-Saharan Africa?
    Stankevitz, Kayla
    Schwartz, Katie
    Hoke, Theresa
    Li, Yixuan
    Lanham, Michele
    Mahaka, Imelda
    Mullick, Saiqa
    PLOS ONE, 2019, 14 (06):
  • [36] The preexposure prophylaxis revolution; from clinical trials to programmatic implementation
    Mugo, Nelly R.
    Ngure, Kenneth
    Kiragu, Michael
    Irungu, Elizabeth
    Kilonzo, Nduku
    CURRENT OPINION IN HIV AND AIDS, 2016, 11 (01) : 80 - 86
  • [37] Factors Associated with Adherence and Concordance Between Measurement Strategies in an HIV Daily Oral Tenofovir/Emtricitibine as Pre-exposure Prophylaxis (Prep) Clinical Trial, Botswana, 2007-2010
    Kebaabetswe, Poloko M.
    Stirratt, Michael J.
    McLellan-Lemal, Eleanor
    Henderson, Faith L.
    Gray, Simone C.
    Rose, Charles E.
    Williams, Tiffany
    Paxton, Lynn A.
    AIDS AND BEHAVIOR, 2015, 19 (05) : 758 - 769
  • [38] Significant insights from a National survey in China: PrEP awareness, willingness, uptake, and adherence among YMSM students
    Liu, Yuanyuan
    Xian, Yidan
    Liu, Xuan
    Cheng, Zhaoyu
    Wei, Siyue
    Wang, Jianping
    Chen, Jiageng
    Li, Changping
    Ma, Jun
    Yang, Jie
    Liu, Fengli
    Yu, Maohe
    Chen, Zhongdan
    Cui, Zhuang
    BMC PUBLIC HEALTH, 2024, 24 (01)
  • [39] "Free Testing and PrEP without Outing Myself to Parents:" Motivation to participate in oral and injectable PrEP clinical trials among adolescent men who have sex with men
    Fisher, Celia B.
    Fried, Adam L.
    Puri, Leah Ibrahim
    Macapagal, Kathryn
    Mustanski, Brian
    PLOS ONE, 2018, 13 (07):
  • [40] A randomized clinical pharmacokinetic trial of Tenofovir in blood, plasma and urine in adults with perfect, moderate and low PrEP adherence: the TARGET study
    Cressey, Tim R.
    Siriprakaisil, Oraphan
    Klinbuayaem, Virat
    Quame-Amaglo, Justice
    Kubiak, Rachel W.
    Sukrakanchana, Pra-Ornsuda
    Than-in-at, Kanchana
    Baeten, Jared
    Sirirungsi, Wasna
    Cressey, Ratchada
    Drain, Paul K.
    BMC INFECTIOUS DISEASES, 2017, 17